Mast cell infiltration associated with tubulointerstitial fibrosis in chronic Aristolochic Acid Nephropathy

Human and Experimental Toxicology

Volumn 24, Issue 2, 2005, Pages 41-47

  Wu, Yichao ^a   Liu, Zhihong ^a   Hu, Weixin ^a   Li, Leishi ^a  

^a NANJING UNIVERSITY   (China)

Author keywords

Aristolochic Acid Nephropathy; Macrophages; Mast cells; Myofibroblasts; Renal fibrosis; Toxicological pathology

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ARISTOLOCHIC ACID; CD68 ANTIGEN; CHINESE DRUG; CREATININE; MONOCLONAL ANTIBODY; MU TONG; TRYPTASE; UNCLASSIFIED DRUG;

ACUTE DISEASE; ADULT; AGED; ARISTOLOCHIC ACID NEPHROPATHY; ARTICLE; CELL INFILTRATION; CELL PROLIFERATION; CHRONIC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE COURSE; DNA ADDUCT; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOLOGY; KIDNEY DISEASE; KIDNEY FIBROSIS; KIDNEY INTERSTITIUM; KIDNEY PARENCHYMA; KIDNEY TUBULE BASEMENT MEMBRANE; MACROPHAGE; MALE; MAST CELL; MYOFIBROBLAST; PATHOGENESIS; PERIODIC ACID SCHIFF STAIN; PRIORITY JOURNAL; SCHOOL CHILD;

ACUTE DISEASE; ADULT; AGED; ARISTOLOCHIC ACIDS; CELL PROLIFERATION; CHILD; CHRONIC DISEASE; DISEASE PROGRESSION; FEMALE; FIBROSIS; HUMANS; MALE; MAST CELLS; MIDDLE AGED; NEPHRITIS, INTERSTITIAL;

EID: 17144423878     PISSN: 09603271     EISSN: None     Source Type: Journal    
DOI: 10.1191/0960327105ht502oa     Document Type: Article

References (22)

1. Cosyns JP. Aristolochic acid and 'Aristolochic Acid Nephropathy': a review of the evidence to date. Drug Safety 2003; 26: 33-48.
2. Nortier JL, Martinez MC, Schmeiser HH, Arlt VM, Bieler CA, Petein M, Depierreux MF, De Pauw L, Abramowicz D, Vereerstraeten P, Vanherweghem JL. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). New England Journal of Medicine 2000; 342: 1686-92.
3. Chang CH, Wang YM, Yang AH, Chiang SS. Rapidly progressive interstitial renal fibrosis associated with Chinese herbal medications. American Journal of Nephrology 2001; 21: 441-48.
4. Bieler CA, Stiborova M, Wiessler M, Cosyns JP, van Ypersele de Strihou C, Schmeiser HH. 32P-post-labelling analysis of DNA adducts formed by aristolochic acid in tissues from patients with Aristolochic Acid Nephropathy. Carcinogenesis 1997; 18: 1063-67.
5. Yang N, Wu LL, Nikolic-Paterson DJ, Ng YY, Yang WC, Mu W, Gilbert RE, Cooper ME, Atkins RC, Lan HY. Local macrophage and myofibroblast proliferation in progressive renal injury in the rat remnant kidney. Nephrology Dialysis Transplantation 1998; 13: 1967-74.
6. Jones SE, Kelly DJ, Cox AJ, Zhang Y, Gow RM, Gilbert RE. Mast cell infiltration and chemokine expression in progressive renal disease. Kidney International 2003; 64: 906-13.
7. Goto E, Honjo S, Yamashita H, Shomori K, Adachi H, Ito H. MCs in human allografted kidney: correlation with interstitial fibrosis. Clinical Transplantation 2002; 16 (Suppl 8): 7-11.
8. Schwartz LB, Bradford TR: Regulation of tryptase from human lung MCs by heparin: Stabilization of the active tetramer. Journal of Biological Chemistry 1986; 261: 7372-79.
9. Alpers CE, Pichler R, Johnson RJ. Phenotypic features of cortical interstitial cells potentially important in fibrosis. Kidney International Supplement 1996; 54: S28-S31.
10. Sato N, Takahashi D, Chen SM, Tsuchiya R, Mukoyama T, Yamagata S, Ogawa M, Yoshida M, Kondo S, Satoh N, Ueda S. Acute nephrotoxicity of aristolochic acids in mice. Journal of Pharmacy and Pharmacology 2004; 56: 221-29.
11. Martinez MC, Nortier J, Vereerstraeten P, Vanherweghem JL. Progression rate of Chinese herb nephropathy: impact of Aristolochia fangchi ingested dose. Nephrology Dialysis Transplantation 2002; 17: 408-12.
12. Puxeddu I, Piliponsky AM, Bachelet I, Levi-Schaffer F. MCs in allergy and beyond. International Journal of Biochemistry Cell Biology 2003; 35: 1601-607.
13. Gordon JR, Burd PR, Galli SJ. MCs as a source of multifunctional cytokines. Immunology Today 1990; 11: 458-64.
14. Ehara T, Shigematsu H. Contribution of mast cells to the tubulointerstitial lesions in IgA nephritis. Kidney International 1998; 54: 1675-83.
15. Lajoie G, Nadasdy T, Laszik Z, Blick KE, Silva FG. MCs in acute cellular rejection of human renal allografts. Modern Pathology 1996; 9: 1118-25.
16. Hiromura K, Kurosawa M, Yano S, Naruse T. Tubulointerstitial mast cell infiltration in glomerulonephritis. American Journal of Kidney Disease 1998; 32: 593-99.
17. Garcia GE, Xia Y, Harrison J, Wilson CB et al. Mononuclear cell-infiltrate inhibition by blocking macrophage-derived chemokine results in attenuation of developing crescentic glomerulonephritis. American Journal of Pathology 2003; 162: 1061-73.
18. Gailit J, Marchese MJ, Kew RR, Gruber BL. The differentiation and function of myofibroblasts is regulated by mast cell mediators. Journal of Investigative Dermatology 2001; 117: 1113-19.
19. Gabbiani G. The myofibroblast in wound healing and fibrocontractive diseases. Journal of Pathology 2003; 200: 500-503.
20. Toth T, Toth-Jakatics R, Jimi S, Ihara M, Urata H, Takebayashi S. MCs in rapidly progressive glomerulonephritis. Journal American Society of Nephrology 1999; 10: 1498-505.
21. Amerio P, Frezzolini A, Feliciani C, Verdolini R, Teofoli P, De Pita O, Puddu P. Eotaxins and CCR3 receptor in inflammatory and allergic skin diseases: therapeutical implications. Current Drug Targets and Inflammatory Allergy 2003; 2: 81-94.
22. Woo CH, Jeong DT, Yoon SB, Kim KS, Chung IY, Saeki T, Kim JH. Eotaxin induces migration of RBL-2H3 MCs via a Rac-ERK-dependent pathway. Biochem Biophys Res Commun 2002; 298: 392-97.